Crizotinib is a targeted therapy (FDA approved in 2011), manufactured by Pfizer and marketed under the brand name Xalkori and Crizalk that targets the<unk> /ALK fusion gene. Ceritinib is a second generation targeted therapy (FDA approved in 2014), manufactured by Novartis and sold under the brand name Zykadia that also targets the<unk>  fusion gene, but as a second generation drug it has a smaller molecule that allows superior penetration of the Blood Brain Barrier (BBB) over Crizotinib and is more capable of protecting the Central Nervous System (CNS). Alectinib another second generation targeted therapy and was approved (for this) by Japan in 2014 and by US FDA in 2015., manufactured by Genentech and marketed under the brand name Alecensa. Brigatinib a second generation targeted therapy (FDA approved in 2017), manufactured by Takeda and is marketed under the brand name Alunbrig. Ensartinib is a second generation targeted therapy (trial drug X-396), manufactured by XCovery. Lorlatinib is a third generation targeted therapy (awaiting FDA approval under trial drug PF-6463922), manufactured by Pfizer. TPX-0005 is a new third generation targeted therapy drug trial.
EML4-ALK positive lung cancer
Limited-stage small cell lung carcinoma
Salivary gland–like carcinoma of the lung
complications of Mesothelioma
Thymoma with immunodeficiency
Combined small-cell lung carcinoma
Waldenström macroglobulinemia
Atypical pulmonary carcinoid tumour